表紙
市場調査レポート

アレルギー性鼻炎結膜炎:パイプライン製品の分析

Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 255930
出版日 ページ情報 英文 82 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
アレルギー性鼻炎結膜炎:パイプライン製品の分析 Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015
出版日: 2015年09月16日 ページ情報: 英文 82 Pages
概要

アレルギー性鼻炎結膜炎は最も頻繁に生じているアレルギー性疾患です。主な症状には、鼻づまりや鼻水、流涙、目蓋の腫れ、口・喉・耳・顔面のかゆみ、咳などがあります。主な疾病素質として、喫煙や汚染物質、煤煙、化学薬品などが挙げられます。主な治療薬には、抗ヒスタミン剤やコルチコステロイド、鼻づまり薬などがあります。

当レポートでは、世界各国でのアレルギー性鼻炎結膜炎治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 分析範囲

アレルギー性鼻炎結膜炎の概要

治療薬の開発

  • アレルギー性鼻炎結膜炎向けパイプライン製品:概要

各企業で開発中のアレルギー性鼻炎結膜炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品

アレルギー性鼻炎結膜炎治療薬:開発中の製品の一覧 (企業別)

アレルギー性鼻炎結膜炎治療薬の開発に従事している企業

  • ALK-Abello A/S
  • Allergopharma Joachim Ganzer KG
  • Allergy Therapeutics Plc
  • Bial
  • BioTech Tools s.a.
  • Circassia Pharmaceuticals Plc
  • Greer Laboratories, Inc.
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.
  • Laboratorios LETI S.L.
  • Oxagen Limited
  • Stallergenes S.A.

アレルギー性鼻炎結膜炎:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • AL-0704rP
    • 製品概要
    • 機能メカニズム
    • 研究開発 (R&D) の進展状況
  • アレルギー性鼻炎・アレルギー性鼻炎結膜炎のアレルゲン
  • アレルギー性鼻炎・アレルギー性鼻炎結膜炎・アレルギー性喘息のアレルゲン
  • シラカバ花粉によるアレルギー性鼻炎・アレルギー性鼻炎結膜炎のアレルゲン
  • シラカバ花粉によるアレルギー性鼻炎結膜炎のアレルゲン
  • アリゾナスギ (Arizona cypress) 花粉によるアレルギー性鼻炎結膜炎のアレルゲン
  • イエダニによるアレルギー性鼻炎結膜炎のアレルゲン
  • 牧草花粉によるアレルギー性鼻炎・アレルギー性鼻炎結膜炎のアレルゲン
  • オカヒジキ カリ (Salsola Kali) 花粉によるアレルギー性鼻炎結膜炎のアレルゲン
  • Allergovac
  • ASP-4070
  • gp-ASIT
  • MK-8237
  • OC-000459
  • オリーブ花粉エキス
  • Pollinex Quattro Grass
  • ブタクサ花粉エキス
  • rBet v1
  • rBet v1-FV
  • rPhleum
  • アレルギー性鼻炎結膜炎・イエダニアレルギー向けワクチン
  • 喘息・牧草花粉症・アレルギー性鼻炎結膜炎向けワクチン

アレルギー性鼻炎結膜炎治療薬:最新の薬剤プロファイル

アレルギー性鼻炎結膜炎治療薬:開発が休止状態の製品

アレルギー性鼻炎結膜炎治療薬:開発が中止された製品

アレルギー性鼻炎結膜炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース (全6件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7101IDB

Summary

Global Markets Direct's, 'Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2015', provides an overview of the Allergic Rhino-Conjunctivitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Allergic Rhino-Conjunctivitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Allergic Rhino-Conjunctivitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Allergic Rhino-Conjunctivitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Allergic Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Allergic Rhino-Conjunctivitis Overview
  • Therapeutics Development
    • Pipeline Products for Allergic Rhino-Conjunctivitis - Overview
  • Allergic Rhino-Conjunctivitis - Therapeutics under Development by Companies
  • Allergic Rhino-Conjunctivitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Allergic Rhino-Conjunctivitis - Products under Development by Companies
  • Allergic Rhino-Conjunctivitis - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergopharma Joachim Ganzer KG
    • Allergy Therapeutics Plc
    • Bial - Portela & Ca, S.A.
    • BioTech Tools s.a.
    • Circassia Pharmaceuticals Plc
    • Greer Laboratories, Inc.
    • HAL Allergy BV
    • Immunomic Therapeutics, Inc.
    • Laboratorios LETI S.L.
    • Oxagen Limited
    • Stallergenes S.A.
  • Allergic Rhino-Conjunctivitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AL-0704rP - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Cupressus Arizonica Pollen Induced Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for Salsola Kali Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergovac - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-4070 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gp-ASIT - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MK-8237 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OC-000459 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Olea Europaea Pollen Extract - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pollinex Quattro Grass - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ragweed Pollen Extract - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rBet v1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rBet v1-FV - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rPhleum - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Allergic Rhino-Conjunctivitis - Recent Pipeline Updates
  • Allergic Rhino-Conjunctivitis - Dormant Projects
  • Allergic Rhino-Conjunctivitis - Discontinued Products
  • Allergic Rhino-Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen
      • May 18, 2014: BioTech Tools will be present at the EAACI congress
      • Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology
      • Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics
      • Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites
      • Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Allergic Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Allergopharma Joachim Ganzer KG, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca, S.A., H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by BioTech Tools s.a., H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Circassia Pharmaceuticals Plc, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Greer Laboratories, Inc., H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Immunomic Therapeutics, Inc., H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Laboratorios LETI S.L., H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Oxagen Limited, H2 2015
  • Allergic Rhino-Conjunctivitis - Pipeline by Stallergenes S.A., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Allergic Rhino-Conjunctivitis Therapeutics - Recent Pipeline Updates, H2 2015
  • Allergic Rhino-Conjunctivitis - Dormant Projects, H2 2015
  • Allergic Rhino-Conjunctivitis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top